Pharmacovigilance – Products

Johnson & Johnson has announced topline efficacy and safety data from the Phase 3 ENSEMBLE trial. Results demonstrate that the investigational single-dose COVID-19 vaccine met all primary and key secondary endpoints. The level of protection against moderate to severe COVID-19 was 72% in the US, 66% in Latin America and 57% in South Africa, 28 days post-vaccination.

Novel test supports vaccine development studies critical to aiding researchers in understanding immunity levels and disease progression.

FDA publication demonstrates the advantages of PhysioMimix in drug safety and metabolism applications, over standard techniques.

A new method for the treatment of rheumatoid arthritis using neuroplasticity-altering electrical fields is being developed by scientists, to regulate immune function.

Cybin Inc. today announced the signing of a definitive agreement to acquire 100% of the shares in Adelia Therapeutics Inc.

Lonza today announced a collaboration with a global biopharma company. They both aim to commercialize antibody-drug conjugates.

DeepADMET have announced the successful conclusion of a new AI platform, to identify drug targets more efficiently.

InSphero AG, today announced the strengthening of its Scientific Advisory Board (SAB).

The 7th CSP Blind Test will see the methods in Crystal Structure Prediction put to the test on real targets. The 7 test systems have been sourced from leading experimentalists in industry and academia for prediction.

Download this app note to discover more about binding parameters and high-throughput assays in drug development.